p53 gene in treatment of hepatic carcinoma: Status quo

World Journal of Gastroenterology

Volumn 13, Issue 7, 2007, Pages 985-992

  Guan, Yong Song ^a   La, Zi ^a   Yang, Lin ^a   He, Qing ^a   Li, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Advances; Hepatocellular carcinoma; p53 gene; Prospects; Therapeutic strategies

Indexed keywords

ADENOSINE; ADENOVIRUS VECTOR; ARF PROTEIN; CNHK300 ME; CONTRAST MEDIUM; E1A PROTEIN; E1B PROTEIN; ENDOSTATIN; GLYCOPROTEIN P; HEPATITIS B VIRUS X PROTEIN; IODINATED POPPYSEED OIL; MULTIDRUG RESISTANCE PROTEIN; MUTANT PROTEIN; ONCOLYTIC VIRUS; ONYX 015; PROTEIN BID; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SCH 58500; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTIFICIAL EMBOLISM; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL STRESS; CHEMOEMBOLIZATION; DNA INTEGRATION; DNA REPAIR; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE CONSTRUCT; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE REPRESSION; GENE THERAPY; HUMAN; LIVER CARCINOGENESIS; LIVER CARCINOMA; MULTIDRUG RESISTANCE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

EID: 34047151851     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i7.985     Document Type: Review

References (109)

1. Editorial: Playing with genes. Br Med J 1976; 1: 302
2. Stetten D. What men fear. Perspect Biol Med 1978; 21: 515-523
3. Friedmann T. Progress toward human gene therapy. Science 1989; 244:1275-1281
4. Friedmann T. The evolving concept of gene therapy. Hum Gene Ther 1990; 1: 175-181
5. Goncalves MA. A concise peer into the background, initial thoughts and practices of human gene therapy. Bioessays 2005; 27:506-517
6. Wolff JA, Lederberg J. An early history of gene transfer and therapy. Hum Gene Ther 1994; 5: 469-480
7. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74: 711-738
8. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995; 270: 475-480
9. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 2006; 58: 467-486
10. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006; 25: 3771-3777
11. Muller C. Hepatocellular carcinoma--rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006; 156:404-409
12. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235
13. Cheah PL, Looi LM. p53: an overview of over two decades of study. Malays J Pathol 2001; 23: 9-16
14. Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther 2003; 2: S55-S63
15. Haupt S, Haupt Y. Importance of p53 for cancer onset and therapy. Anticancer Drugs 2006; 17: 725-732
16. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027
17. Ries SJ. Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015. Future Oncol 2005; 1: 763-766
18. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331
19. Balint E E, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001; 85: 1813-1823
20. Selivanova G, Wiman KG. p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 1995; 66:143-180
21. Bykov VJ, Wiman KG. Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann Med 2003; 35: 458-465
22. Hagiwara N, Mechanic LE, Trivers GE, Cawley HL, Taga M, Bowman ED, Kumamoto K, He P, Bernard M, Doja S, Miyashita M, Tajiri T, Sasajima K, Nomura T, Makino H, Takahashi K, Hussain SP, Harris CC. Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers. Cancer Res 2006; 66: 8309-8317
23. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778-3786
24. Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, Fersht AR. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". J Mol Biol 2004; 336: 187-196
25. Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR. Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA 1997; 94: 14338-14342
26. El Far MA, Atwa MA, Yahya RS, El Basuni MA. Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt. Clin Chem Lab Med 2006; 44: 653-656
27. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006; 66: 4766-4773
28. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87:1973-1977
29. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999; 30:413-421
30. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-2071
31. Hirohashi S. Pathology and molecular mechanisms of multistage human hepatocarcinogenesis. Princess Takamatsu Symp 1991; 22: 87-93
32. Kondo M, Marusawa H, Ueda Y, Katsurada A, Kawasome C, Takami S, Kinoshita M, Ikai I, Yamaoka Y, Chiba T. Diverse p53 gene aberration in hepatocellular carcinoma detected by dual-color fluorescence in situ hybridization. J Gastroenterol Hepatol 2004; 19: 1066-1073
33. Dewantoro O, Gani RA, Akbar N. Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53. Acta Med Indones 2006; 38: 154-159
34. Cho JW, Park K, Kweon GR, Park JC, Lee JQ Baek WK, Jang BC, Suh SI, Suh MH. Modulation of cell death sensitivity by mutant p53 in HCV core-expressing cells. Int J Mol Med 2005; 15:475-480
35. Wu CG, Salvay DM, Forgues M, Valerie K, Farnsworth J, Markin RS, Wang XW. Distinctive gene expression profiles associated with Hepatitis B virus x protein. Oncogene 2001; 20: 3674-3682
36. Mathonnet G, Lachance S, Alaoui-Jamali M, Drobetsky EA. Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. Mutat Res 2004; 554: 305-318
37. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, Geller DA, Will H, Harris CC. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 1997; 94: 14707-14712
38. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clin Virol 2005; 34 Suppl 1: S75-S78
39. Zhang X, Dong N, Yin L, Cai N, Ma H, You J, Zhang H, Wang H, He R, Ye L. Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol 2005; 77: 374-381
40. Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer 2005; 35: 53-60
41. Lacabanne V, Viguier M, Guillet JG, Choppin J. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 1996; 26: 2635-2639
42. Eipel C, Schuett H, Glawe C, Bordel I, Menger MD, Vollmar B. Pifithrin-alpha induced p53 inhibition does not affect liver regeneration after partial hepatectomy in mice. J Hepatol 2005; 43:829-835
43. Lutz W, Nowakowska-Swirta E. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process. Int J Occup Med Environ Health 2002; 15: 209-218
44. Muller M, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, Stremmel W, Volkmann M, Galle PR. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol 2006; 29: 973-980
45. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102: 17448-17453
46. Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1999; 1: 500-509
47. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245
48. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-1132
49. Zhang, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 2000; 6: 393-416
50. Stearns T, Willingham MC, Botstein D, Kahn RA. ADP-ribosylation factor is functionally and physically associated with the Golgi complex. Proc Natl Acad Sci USA 1990; 87: 1238-1242
51. Wen LT, Knowles AF. Extracellular ATP and adenosine induce cell apoptosis of human hepatoma LiJA cells via the A3 adenosine receptor. Br J Pharmacol 2003; 140: 1009-1018
52. Rocha S, Perkins ND. ARF the integrator: linking NF-kappaB, p53 and checkpoint kinases. Cell Cycle 2005; 4: 756-759
53. Brown DR, Deb S, Munoz RM, Subler MA, Deb SP. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol Cell Biol 1993; 13: 6849-6857
54. Lin J, Zhu MH. Interactive pathway of ARF-mdm2-p53. Ai Zheng 2003; 22:328-330
55. Guo Y, Zeng Y, Wang K, Zhu X, Luo H, Zheng M, Li M, Chen J. Therapeutic potential of recombinant adenovirus expressing p53 in hepatocellular carcinoma cell lines. Zhonghua Ganzangbing Zazhi 2001; 9 Suppl: 43-45
56. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 2005; 124 Suppl: S16-S28
57. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 2004; 53: 519-526
58. Li YX, Lin ZB, Tan HR. Wild type p53 increased chemo-sensitivity of drug-resistant human hepatocellular carcinoma Be17402/5-FU cells. Acta Pharmacol Sin 2004; 25: 76-82
59. Zhang X, Godbey WT. Viral vectors for gene delivery in tissue engineering. Adv Drug Deliv Rev 2006; 58:515-534
60. Buning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M. Receptor targeting of adeno-associated virus vectors. Gene Ther 2003; 10: 1142-1151
61. Miyazaki M, Obata Y, Abe K, Furusu A, Koji T, Tabata Y, Kohno S. Gene transfer using nonviral delivery systems. Perit Dial Int 2006; 26: 633-640
62. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22: 1546-1552
63. Kodama K, Katayama Y, Shoji Y, Nakashima. H. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem 2006; 13: 2155-2161
64. Noireaux V, Libchaber A. A vesicle bioreactor as a step toward an artificial cell assembly. Proc Natl Acad Sci USA 2004; 101: 17669-17674
65. Kim JW, Lee HS. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model. Int J Mol Med 2004; 14: 529-535
66. Barraud L, Merle P, Soma E, Lefrancois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trepo C, Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005; 42: 736-743
67. Tada M, Hatano E, Taura K, Nitta T, Koizumi N, Ikai I, Shimahara Y. High volume hydrodynamic injection of plasmid DNA via the hepatic artery results in a high level of gene expression in rat hepatocellular carcinoma induced by diethylnitrosamine. J Gene Med 2006; 8: 1018-1026
68. Meyer F, Ball V, Schaaf P, Voegel JC, Ogier J. Polyplex-embedding in polyelectrolyte multilayers for gene delivery. Biochim Biophys Acta 2006; 1758: 419-422
69. Uto H, Ido A, Hori T, Hirono S, Hayashi K, Tamaoki T, Tsubouchi H. Hepatoma-specific gene therapy through retrovirus-mediated and targeted gene transfer using an adenovirus carrying the ecotropic receptor gene. Biochem Biophys Res Commun 1999; 265: 550-555
70. Min KA, Lee SK, Kim CK. Improved gene expression pattern using Epstein-Barr virus (EBV)-based plasmid and cationic emulsion. Biomaterials 2005; 26: 1063-1070
71. Wilson GM, Deeley RG. An episomal expression vector system for monitoring sequence-specific effects on mRNA stability in human cell lines. Plasmid 1995; 33: 198-207
72. Kim YI, Chung JW, Park JH, Han JK, Hong JW, Chung H. Intraarterial gene delivery in rabbit hepatic tumors: transfection with nonviral vector by using iodized oil emulsion. Radiology 2006; 240: 771-777
73. Cherubini G, Petouchoff T, Grossi M, Piersanti S, Cundari E, Saggio I. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 2006; 5: 2244-2252
74. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623
75. Goncalves MA, de Vries AA. Adenovirus: from foe to friend. Rev Med Virol 2006; 16: 167-186
76. Zhang LQ Mei YF, Wadell G. Human adenovirus serotypes 4 and 11 show higher binding affinity and infectivity for endothelial and carcinoma cell lines than serotype 5. J Gen Virol 2003; 84: 687-695
77. Ebner K, Rauch M, Preuner S, Lion T. Typing of human adenoviruses in specimens from immunosuppressed patients by PCR-fragment length analysis and real-time quantitative PCR. J Clin Microbiol 2006; 44: 2808-2815
78. Jacobs SC, Davison AJ, Carr S, Bennett AM, Phillpotts R, Wilkinson GW. Characterization and manipulation of the human adenovirus 4 genome. J Gen Virol 2004; 85: 3361-3366
79. Bos JL, Jochemsen AG, Bernards R, Schrier PI, van Ormondt H, van der Eb AJ. Deletion mutants of region E1a of AD12 E1 plasmids: effect on oncogenic transformation. Virology 1983; 129: 393-400
80. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5: 1079-1088
81. Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect, Clin Cancer Res 1999; 5: 1015-1023
82. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kim DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645
83. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-9478
84. Stoff-Khalili MA, Dall P, Curiel DT. Gene therapy for carcinoma of the breast. Cancer Gene Ther 2006; 13: 633-647
85. Li G, Sham J, Yang J, Su C, Xue H, Chua D, Sun L, Zhang Q, Cui Z, Wu M, Qian Q. Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int J Cancer 2005; 113: 640-648
86. Qian Q, Sham J, Che X, Xu J, Xue H, Cui Z, Zhu B, Wu M. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously. Chin Med J (Engl) 2002; 115: 1213-1217
87. Li GC, Yang JM, Nie MM, Su CG, Sun LC, Qian YZ, Fang GE, Sham J, Wu MC, Qian QJ. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocelIular carcinoma. Chin Med J (Engl) 2005; 118: 179-185
88. Ye Z, Wang X, Hao S, Zhong J, Xiang J, Yang J. Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model. Cancer Biother Radiopharm 2006; 21: 225-234
89. Yoon SK, Armentano D, Wands JR, Mohr L. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gene Ther 2001; 8: 573-579
90. Kuriyama S, Yoshiji H, Nakai S, Deguchi A, Uchida N, Kimura Y, Inoue H, Kinekawa. F, Ogawa M, Nonomura T, Masaki T, Kurokohchi K, Watanabe S. Adenovirus-mediated gene transfer into rat livers: comparative study of retrograde intrabiliary and antegrade intraportal administration. Oncol 2005; 13: 69-74
91. White SA, LoBuglio AF, Arani RB, Pike MJ, Moore SE, Barlow DL, Conry RM. Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine. J Gene Med 2000; 2: 135-140
92. Xie X, Forsmark CE, Lau JY. Effect of bile and pancreatic juice on adenoviral-mediated gene delivery: implications on the feasibility of gene delivery through ERCP. Dig Dis Sci 2000; 45: 230-236
93. Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase I colorectal cancer trial. Cancer Gene Ther 2006; 13: 169-181
94. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006; 6: 55-61
95. Roche A, Franco D, Dhumeaux D, Bismuth H, Doyon D. Emergency hepatic arterial embolization for secondary hypercalcemia in hepatocellular carcinoma. Radiology 1979; 133: 315-316
96. Suzuki K, Kono N, Ono A, Osuga. Y, Kiyokawa H, Mineo I, Matsuda Y, Miyoshi S, Kawata S, Minami Y. Transcatheter arterial chemo-embolization for humoral hypercalcemia. of hepatocellular carcinoma. Gastroenterol Jpn 1988; 23: 29-36
97. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2:474-479
98. Llanos S, Efeyan A, Monsech J, Dominguez O, Serrano M. A high-throughput loss-of-function screening identifies novel p53 regulators. Cell Cycle 2006; 5: 1880-1885
99. Feitelson MA, Pan J, Lian Z. Early molecular and genetic determinants of primary liver malignancy. Surg Clin North Am 2004; 84: 339-354
100. Zhu MH, Ni CR, Zhu Z, Li FM, Zhang SM. Determination of expression of eight p53-related genes in hepatocellular carcinoma with tissue microarrays. Ai Zheng 2003; 22: 680-685
101. Attallah AM, Abdel-Aziz MM, El-Sayed AM, Tabll AA. Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Detect Prev 2003; 27: 127-131
102. Maron DJ, Tada H, Moscioni AD, Tazelaar J, Fraker DL, Wilson JM, Spitz FR. Intra-arterial delivery of a recombinant adenovirus does not increase gene transfer to tumor cells in a rat model of metastatic colorectal. carcinoma. Mol Ther 2001; 4: 29-35
103. Smith L, Byers JF. Gene therapy in the post-Gelsinger era. JONAS Healthc Law Ethics Regul 2002; 4: 104-110
104. Walters J. Why did Jesse die? Update 2001; 17: E1
105. Vinyals A, Peinado MA, Gonzalez-Garrigues M, Monzo M, Bonfil RD, Fabra A. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther 1999; 6: 22-33
106. Moretti F, Nanni S, Farsetti A, Narducci M, Crescenzi M, Giuliacci S, Sacchi A, Pontecorvi A. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 2000; 85: 302-308
107. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells, Oncogene 1997; 14: 729-740
108. Miao J, Chen GG, Chun SY, Yun JP, Chak EC, Ho RL, Lai PB. Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma. Int J Cancer 2006; 119: 1985-1993
109. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490